Diagnostic and Prognostic Markers of Chronic Heart Failure in Patients with Occupational Chronic Obstructive Pulmonary Disease

Aim      Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are a common comorbidity. Professional chronic obstructive pulmonary disease (PCOPD) is a specific phenotype, which suggests peculiarities in the development of HF. Difficulties of HF diagnosis in such patients determine the relevance of searching for additional markers. The aim of the study was identifying HF markers in patients with PCOPD.

Material and methods  This single-site, cohort, prospective, observational study included 345 patients. The main group consisted of PCOPD patients; the comparison group consisted of patients with COPD induced by tobacco smoking; and the control group included conventionally healthy individuals. The groups were matched by the index of coincidence; pairs were matched at 1:1 by the “nearest neighbor index”; covariates for matching included COPD duration, sex, and age. Each group included 115 patients. The major professional adverse factors were silica-containing dust and organic solvents. COPD was diagnosed according to GOLD criteria; HF was diagnosed in accordance with Russian clinical guidelines. The markers were determined by multifactorial logistic regression. Likelihood of events with allowance for the time to the event was analyzed by the Kaplan-Meier method.

Results HF in PCOPD patients was characterized by biventricular damage, preserved left ventricular ejection fraction, and frequent hospitalizations for decompensation (17.5 % vs. 9.5 % for COPD in smokers). HF markers in patients with PCOPD included the length of work of more than 20 years, pulmonary artery systolic pressure (PASP) higher than 35 mm Hg according to data of Doppler echocardiography, diffusing capacity of lungs for carbon monoxide (DL_CO) less than 50 %, increased serum concentrations of CC-chemokine ligand 18 (CCL18), S-100‑beta protein, and N-terminal pro-brain natriuretic peptide (NT-pro-BNP). Diagnostic sensitivity of the multifactorial model was 84 % and specificity was 81 %. Two models were proposed for purposes of screening, which included the following parameters: length of work, exposure to aromatic hydrocarbons, decreased distance in 6-min walk test by more than 60 m per year and length of work, exposure to inorganic dust, and decreased forced expiratory volume during the first second by more than 55 ml per year.

Conclusion      The markers for development of HF in PCOPD patients are length of work >20 years, PASP >35 mm Hg, DL_CO <50 %, and increased serum concentrations of CCL18, S-100‑beta protein, and NT-pro-BNP.

1. Figueira Gonçalves JM, Dorta Sánchez R, Rodríguez Pérez M del C, Viña Manrique P, Díaz Pérez D, Guzmán Saenz C et al. Comorbilidad cardiovascular en pacientes con enfermedad pulmonar obstructiva crónica en Canarias (estudio CCECAN). Clínica e Investigación en Arteriosclerosis. 2017;29(4):149–56. DOI: 10.1016/j.arteri.2017.01.003

2. Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R et al. Association of Cardiovascular Disease With Respiratory Disease. Journal of the American College of Cardiology. 2019;73(17):2166–77. DOI: 10.1016/j.jacc.2018.11.063

3. Malerba M, Ragnoli B, Salameh M, Sennino G, Sorlini ML, Radaeli A et al. Sub-clinical left ventricular diastolic dysfunction in early stage of chronic obstructive pulmonary disease. Journal of Biological Regulators and Homeostatic Agents. 2011;25(3):443–51. PMID: 22023769

4. Gazizyanova V.M., Bulashova O.V., Hazova E.V., Hasanov N.R., Oslopov V.N. Clinical features and prognosis in heart failure patients with chronic obstructive pulmonary diseases. Kardiologiia. 2019;59(6S):51–60. DOI: 10.18087/cardio.2674

5. Sato Y, Yoshihisa A, Oikawa M, Nagai T, Yoshikawa T, Saito Y et al. Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction – A report from the JASPER registry. Journal of Cardiology. 2019;73(6):459–65. DOI: 10.1016/j.jjcc.2019.01.005

6. Portillo K, Torralba Y, Blanco I, Burgos F, Rodriguez -Roisin R, Rios J et al. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2015;10:1313–20. DOI: 10.2147/COPD.S78180

7. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA et al. Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling. New England Journal of Medicine. 2010;362(3):217–27. DOI: 10.1056/NEJMoa0808836

8. López-Sánchez M, Muñoz-Esquerre M, Huertas D, Montes A, Molina-Molina M, Manresa F et al. Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction: Inflammatory pattern in COPD and LVDD. The Clinical Respiratory Journal. 2017;11(6):859–66. DOI: 10.1111/crj.12428

9. Sakolchik M.A., Gorblyansky Yu.Yu., Podmogilnaya K.V., Fedyakina V.V. Epidemiological features of occupational chronic obstructive lung disease. Occupational Health and Industrial Ecology. 2018;7:51–5. DOI: 10.31089/1026-9428-2018-7-51-55

10. Paulin LM, Diette GB, Blanc PD, Putcha N, Eisner MD, Kanner RE et al. Occupational Exposures Are Associated with Worse Morbidity in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2015;191(5):557– 65. DOI: 10.1164/rccm.201408-1407OC

11. Muñoz-Ferrer A, Rodriguez-Pons L, Garcia-Olivé I, Lupón J, de Antonio M, Domingo M et al. Airflow limitation in patients with heart failure: Prevalence and associated factors. Medicina Clínica. 2019;153(5):191–5. DOI: 10.1016/j.medcli.2018.11.016

12. Avdeev S.N., Gaynitdinova V.V., Tsareva N.A., Merzhoeva Z.M. Natriuretic peptides as markers of development and prognosis of the severity of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Russian Clinical Laboratory Diagnostics. 2018;63(6):333–7.

13. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 report. Av. at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD2020-FINAL-ver1.2-03Dec19_WMV.pdf.

14. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–164. DOI: 10.18087/cardio.2475

15. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. European Respiratory Journal. 2009;34(3):648–54. DOI: 10.1183/09031936.00102509

16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation of spirometry. European Respiratory Journal. 2005;26(2):319–38. DOI: 10.1183/09031936.05.00034805

17. Muñoz-Esquerre M, Aliagas E, López-Sánchez M, Escobar I, Huertas D, Penín R et al. Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine). PLOS ONE. 2017;12(5):e0177218. DOI: 10.1371/journal.pone.0177218

18. Neukamm AMC, Høiseth AD, Hagve T-A, Søyseth V, Omland T. High-sensitivity cardiac troponin T levels are increased in stable COPD. Heart. 2013;99(6):382–7. DOI: 10.1136/heartjnl-2012-303429

19. Deboevere N, Marjanovic N, Sierecki M, Marchetti M, Dubocage M, Magimel E et al. Value of copeptin and the S-100b protein assay in ruling out the diagnosis of stroke-induced dizziness pattern in emergency departments. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2019;27(1):72. DOI: 10.1186/s13049-019-0651-1

20. Bártholo TP, Costa CH da, Rufino R. Evaluation of von Willebrand factor in COPD patients. Jornal Brasileiro de Pneumologia. 2014;40(4):373–9. DOI: 10.1590/S1806-37132014000400004

21. Tretiakov S.V., Shpagina L.A. Spirometry and veloergometry in evaluating physical performance of individuals exposed to organic solvents. Russian Journal of Occupational Health and Industrial Ecology. 2015;6:27–31.

22. Bukhtiyarov I.V., Chebotarev A.G., Courierov N.N., Sokur O.V. Topical issues of improving working conditions and preserving the health of employees of mining enterprises. Russian Journal of Occupational Health and Industrial Ecology. 2019;59(7):424–9. DOI: 10.31089/1026-9428-2019-59-7-424-429

23. Panev N.I., Korotenko O.Yu., Filimonov S.N., Semenova E.A., Panev R.N. Prevalence of cardiovascular pathology in workers of the aluminum industry. Hygiene and sanitation. 2019;98(3):276–9. DOI: 10.18821/0016-9900-2019-98-3-276-279

24. Lawson CA, Mamas MA, Jones PW, Teece L, McCann G, Khunti K et al. Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JAMA Network Open. 2018;1(8):e185489. DOI: 10.1001/jamanetworkopen.2018.5489

25. Westerik JAM, Metting EI, van Boven JFM, Tiersma W, Kocks JWH, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respiratory Research. 2017;18(1):31. DOI: 10.1186/s12931-017-0512-2